keyword
https://read.qxmd.com/read/38758826/pai-1-mediates-acquired-resistance-to-met-targeted-therapy-in-non-small-cell-lung-cancer
#61
JOURNAL ARTICLE
Yin Min Thu, Ken Suzawa, Shuta Tomida, Kosuke Ochi, Shimpei Tsudaka, Fumiaki Takatsu, Keiichi Date, Naoki Matsuda, Kazuma Iwata, Kentaro Nakata, Kazuhiko Shien, Hiromasa Yamamoto, Mikio Okazaki, Seiichiro Sugimoto, Shinichi Toyooka
Mechanisms underlying primary and acquired resistance to MET tyrosine kinase inhibitors (TKIs) in managing non-small cell lung cancer remain unclear. In this study, we investigated the possible mechanisms acquired for crizotinib in MET-amplified lung carcinoma cell lines. Two MET-amplified lung cancer cell lines, EBC-1 and H1993, were established for acquired resistance to MET-TKI crizotinib and were functionally elucidated. Genomic and transcriptomic data were used to assess the factors contributing to the resistance mechanism, and the alterations hypothesized to confer resistance were validated...
2024: PloS One
https://read.qxmd.com/read/38758757/evaluation-of-a-simple-method-for-testing-aztreonam-and-ceftazidime-avibactam-synergy-in-new-delhi-metallo-beta-lactamase-producing-enterobacterales
#62
JOURNAL ARTICLE
Salman Khan, Arghya Das, Deepali Vashisth, Anwita Mishra, Ashima Jain Vidyarthi, Raghav Gupta, Nazneen Nahar Begam, Babita Kataria, Sushma Bhatnagar
NDM-producing carbapenem-resistant bacterial infections became a challenge for clinicians. Combination therapy of aztreonam and ceftazidime-avibactam is a prudent choice for these infections. However, there is still no recommendation of a practically feasible method for testing aztreonam and ceftazidime-avibactam synergy. We proposed a simple method for testing aztreonam and ceftazidime-avibactam synergy and compared it with reference broth micro-dilution and other methods. Carbapenem-resistant Enterobacterales clinical isolates were screened for the presence of the NDM gene by the Carba R test...
2024: PloS One
https://read.qxmd.com/read/38758499/plant-derived-exosome-like-nanoparticles-for-microrna-delivery-in-cancer-treatment
#63
REVIEW
Chun Yi, Linzhu Lu, Zhaosheng Li, Qianqian Guo, Longyun Ou, Ruoyu Wang, Xuefei Tian
Plant-derived exosome-like nanoparticles (PELNs) are natural nanocarriers and effective delivery systems for plant microRNAs (miRNAs). These PELN-carrying plant miRNAs can regulate mammalian genes across species, thereby increasing the diversity of miRNAs in mammals and exerting multi-target effects that play a crucial role in diseases, particularly cancer. PELNs demonstrate exceptional stability, biocompatibility, and targeting capabilities that protect and facilitate the up-take and cross-kingdom communication of plant miRNAs in mammals...
May 17, 2024: Drug Delivery and Translational Research
https://read.qxmd.com/read/38758482/anticancer-potential-of-postbiotic-derived-from-lactobacillus-brevis-and-lactobacillus-casei-in-vitro-analysis-of-breast-cancer-cell-line
#64
JOURNAL ARTICLE
Mahsa Dameshghian, Farzaneh Tafvizi, Maryam Tajabadi Ebrahimi, Reza Hosseini Doust
Breast cancer has emerged as the most widespread and dangerous type of malignancy among women worldwide. Postbiotics have recently emerged as a promising novel adjunct in breast cancer therapy, due to their immunomodulatory effects and the potential to mitigate the adverse effects of conventional treatments. This study aims to investigate the therapeutic effects of postbiotics derived from Lactobacillus brevis (CSF2) and Lactobacillus casei (CFS5), specifically examining their ability to inhibit cell proliferation and induce apoptosis in MCF-7 breast cancer cells...
May 17, 2024: Probiotics and Antimicrobial Proteins
https://read.qxmd.com/read/38758472/mitophagy-in-health-and-disease-molecular-mechanisms-regulatory-pathways-and-therapeutic-implications
#65
REVIEW
Mark S D'Arcy
Mitophagy, a specialised form of autophagy, selectively targeting damaged or dysfunctional mitochondria, and is crucial for maintaining cellular homeostasis and mitochondrial quality control. Dysregulation of mitophagy contributes to various pathological conditions, including cancer, neurodegenerative and cardiovascular diseases. This review presents a comprehensive analysis of the molecular mechanisms, regulatory pathways, and interplay with other cellular processes governing mitophagy, emphasizing its importance in physiological and pathological contexts...
May 17, 2024: Apoptosis: An International Journal on Programmed Cell Death
https://read.qxmd.com/read/38758470/unraveling-the-mechanistic-interplay-of-mediators-orchestrating-the-neuroprotective-potential-of-harmine
#66
REVIEW
Pankaj Kadyan, Lovedeep Singh
Neurodegenerative diseases (NDDs) encompass a range of conditions characterized by the specific dysfunction and continual decline of neurons, glial cells, and neural networks within the brain and spinal cord. The majority of NDDs exhibit similar underlying causes, including oxidative stress, neuroinflammation, and malfunctioning of mitochondria. Elevated levels of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), alongside decreased expression of brain-derived neurotrophic factor (BDNF) and glutamate transporter subtype 1 (GLT-1), constitute significant factors contributing to the pathogenesis of NDDs...
May 17, 2024: Pharmacological Reports: PR
https://read.qxmd.com/read/38758417/development-of-ebv-related-diffuse-large-b-cell-lymphoma-in-deficiency-of-adenosine-deaminase-2-with-uncontrolled-ebv-infection
#67
JOURNAL ARTICLE
Logan S Gardner, Lachlin Vaughan, Danielle T Avery, Isabelle Meyts, Cindy S Ma, Stuart G Tangye, Winny Varikatt, Ming-Wei Lin
Deficiency of Adenosine Deaminase 2 (DADA2) patients presenting with primary immunodeficiency are at risk of uncontrolled EBV infection and secondary malignancies including EBV-related lymphoproliferative disorders (LPD). This paper describes the first case of EBV related diffuse large B-cell lymphoma in a patient with DADA2 and uncontrolled EBV infection. Consideration should be given to monitoring for EBV viraemia and to preventative EBV specific therapy in DADA2 and patients with at risk primary immunodeficiencies...
May 17, 2024: Journal of Clinical Immunology
https://read.qxmd.com/read/38758238/genome-wide-loss-of-heterozygosity-predicts-aggressive-treatment-refractory-behavior-in-pituitary-neuroendocrine-tumors
#68
JOURNAL ARTICLE
Andrew L Lin, Vasilisa A Rudneva, Allison L Richards, Yanming Zhang, Hyung Jun Woo, Marc Cohen, Jamie Tisnado, Nazanin Majd, Sharon L Wardlaw, Gabrielle Page-Wilson, Soma Sengupta, Frances Chow, Bernard Goichot, Byram H Ozer, Jorg Dietrich, Lisa Nachtigall, Arati Desai, Tina Alano, Shahiba Ogilive, David B Solit, Tejus A Bale, Marc Rosenblum, Mark T A Donoghue, Eliza B Geer, Viviane Tabar
Pituitary neuroendocrine tumors (PitNETs) exhibiting aggressive, treatment-refractory behavior are the rare subset that progress after surgery, conventional medical therapies, and an initial course of radiation and are characterized by unrelenting growth and/or metastatic dissemination. Two groups of patients with PitNETs were sequenced: a prospective group of patients (n = 66) who consented to sequencing prior to surgery and a retrospective group (n = 26) comprised of aggressive/higher risk PitNETs...
May 17, 2024: Acta Neuropathologica
https://read.qxmd.com/read/38758189/global-epidemiology-and-antimicrobial-resistance-of-enterobacterales-harbouring-genes-encoding-oxa-48-like-carbapenemases-insights-from-the-results-of-the-antimicrobial-testing-leadership-and-surveillance-atlas-programme-2018-2021
#69
JOURNAL ARTICLE
Yu-Lin Lee, Wei-Yao Wang, Wen-Chien Ko, Po-Ren Hsueh
OBJECTIVES: The recent emergence of carbapenem-resistant Enterobacterales poses a major and escalating threat to global public health. This study aimed to analyse the global distribution and antimicrobial resistance of Enterobacterales harbouring variant OXA-48-like carbapenemase-related genes. METHODS: Enterobacterales isolates were collected from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme during 2018-2021. Comprehensive antimicrobial susceptibility testing and β-lactamase gene detection were also conducted, along with statistical analysis of the collected data...
May 17, 2024: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/38758119/effect-of-hla-genotype-on-anti-pd-1-antibody-treatment-for-advanced-renal-cell-carcinoma-in-the-snip-rcc-study
#70
JOURNAL ARTICLE
Tokiyoshi Tanegashima, Masaki Shiota, Nobuhiro Fujiyama, Shintaro Narita, Tomonori Habuchi, Genshiro Fukuchi, Dai Takamatsu, Yoshinao Oda, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, Wataru Obara, Nobuo Shinohara, Kiyohide Fujimoto, Masahiro Nozawa, Kojiro Ohba, Chikara Ohyama, Katsuyoshi Hashine, Shusuke Akamatsu, Tomomi Kamba, Koji Mita, Momokazu Gotoh, Shuichi Tatarano, Masato Fujisawa, Yoshihiko Tomita, Shoichiro Mukai, Keiichi Ito, Shoji Tokunaga, Masatoshi Eto
Immune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual HLA genotypes on the efficacy of an anti-PD-1 Ab, nivolumab, in treating advanced RCC. Patient enrollment was conducted across 23 institutions in Japan from August 19, 2019, to September 30, 2020, with follow-up concluding on March 31, 2021. HLA genotype imputation of HLA-A, B, and C, DQB1, and DRB1 loci was performed...
May 17, 2024: Journal of Immunology
https://read.qxmd.com/read/38758004/phenotypic-amikacin-resistance-may-not-indicate-poor-response-to-amikacin-in-mycobacterium-avium-complex-pulmonary-disease
#71
JOURNAL ARTICLE
L M Minuk, S K Brode, M Mehrabi, M K Sharma, M Stobart, H Soualhine, T K Marras
When using amikacin to treat Mycobacterium avium complex pulmonary disease (MAC-PD), a minimum inhibitory concentration resistance breakpoint of ≥64 mcg/mL is recommended. We explored whether amikacin resistance characterized by phenotypic drug susceptibility testing was associated with clinical outcomes or mutational resistance in a retrospective cohort of patients with MAC-PD. Despite little aminoglycoside exposure, amikacin resistance was common in our MAC-PD patients but was not associated with worse outcomes or rrs gene mutations...
May 17, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38757913/mllt6-atf2-axis-restrains-breast-cancer-progression-by-driving-ddit3-4-expression
#72
JOURNAL ARTICLE
Qing Yu, Jiayi Zhao, Anli Yang, Xiangxin Li
Epigenetic deregulation is strongly associated with tumour progression. The identification of natural tumour suppressors to overcome cancer metastasis is urgent for cancer therapy. We investigate whether myeloid/lymphoid or mixed-lineage leukaemia translocated (MLLT) family members contribute to breast cancer progression and found that high MLLT6 expression predicted a better prognosis and that gradually decreased MLLT6 expression was accompanied by breast cancer malignancy. MLLT6 was downregulated by hypoxia-induced enrichment of DNMT1 at the MLLT6 promoter...
May 17, 2024: Molecular Cancer Research: MCR
https://read.qxmd.com/read/38757788/incident-heart-failure-in-chronic-kidney-disease-proteomics-informs-biology-and-risk-stratification
#73
JOURNAL ARTICLE
Ruth F Dubin, Rajat Deo, Yue Ren, Jianqiao Wang, Alexander R Pico, Josyf C Mychaleckyj, Julia Kozlitina, Victoria Arthur, Hongzhe Lee, Amil Shah, Harold Feldman, Nisha Bansal, Leila Zelnick, Panduranga Rao, Nidhi Sukul, Dominic S Raj, Rupal Mehta, Sylvia E Rosas, Zeenat Bhat, Matthew R Weir, Jiang He, Jing Chen, Mayank Kansal, Paul L Kimmel, Vasan S Ramachandran, Sushrut S Waikar, Mark R Segal, Peter Ganz
BACKGROUND AND AIMS: Incident heart failure (HF) among individuals with chronic kidney disease (CKD) incurs hospitalizations that burden patients and health care systems. There are few preventative therapies, and the Pooled Cohort equations to Prevent Heart Failure (PCP-HF) perform poorly in the setting of CKD. New drug targets and better risk stratification are urgently needed. METHODS: In this analysis of incident HF, SomaScan V4.0 (4638 proteins) was analysed in 2906 participants of the Chronic Renal Insufficiency Cohort (CRIC) with validation in the Atherosclerosis Risk in Communities (ARIC) study...
May 17, 2024: European Heart Journal
https://read.qxmd.com/read/38757769/co-occurrence-of-glial-fibrillary-acidic-protein-astrocytopathy-in-a-patient-with-leber-s-hereditary-optic-neuropathy-due-to-dnajc30-mutations
#74
Maria Pia Giannoccaro, Luana Morelli, Fortuna Ricciardiello, Vincenzo Donadio, Fiorina Bartiromo, Caterina Tonon, Michele Carbonelli, Giulia Amore, Valerio Carelli, Rocco Liguori, Chiara La Morgia
Leber's hereditary optic neuropathy (LHON) is a mitochondrial disease characterized by visual loss, and rarely associated with extraocular manifestations including multiple sclerosis-like lesions. The association of LHON and neuromyelitis optica spectrum disorders has rarely been reported. Here is reported a case of glial fibrillary acidic protein astrocytopathy presenting with area postrema syndrome in a patient with previously diagnosed recessive LHON due to mutations in the nuclear gene DNAJC30. This case emphasizes the necessity of extensive investigations for other treatable conditions in patients with LHON and otherwise unexplained extraocular involvement and the possibility that also visual symptoms can respond to immune therapy...
May 17, 2024: European Journal of Neurology
https://read.qxmd.com/read/38757536/advanced-micro-nano-electroporation-for-gene-therapy-recent-advances-and-future-outlook
#75
REVIEW
Feng Liu, Rongtai Su, Xinran Jiang, Siqi Wang, Wei Mu, Lingqian Chang
Gene therapy is a promising disease treatment approach by editing target genes, and thus plays a fundamental role in precision medicine. To ensure gene therapy efficacy, the effective delivery of therapeutic genes into specific cells is a key challenge. Electroporation utilizes short electric pulses to physically break the cell membrane barrier, allowing gene transfer into the cells. It dodges the off-target risks associated with viral vectors, and also stands out from other physical-based gene delivery methods with its high-throughput and cargo-accelerating features...
May 17, 2024: Nanoscale
https://read.qxmd.com/read/38757376/oncogenic-composite-mutations-can-be-predicted-by-co-mutations-and-their-chromosomal-location
#76
JOURNAL ARTICLE
Asli Küçükosmanoglu, Carolien L van der Borden, Lisanne E A de Boer, Roel Verhaak, David Noske, Tom Wurdinger, Teodora Radonic, Bart A Westerman
Genetic heterogeneity in tumors can show a remarkable selectivity when two or more independent genetic events occur in the same gene. This phenomenon, called composite mutation, points toward a selective pressure, which frequently causes therapy resistance to mutation-specific drugs. Since composite mutations have been described to occur in sub-clonal populations, they are not always captured through biopsy sampling. Here, we provide a proof of concept to predict composite mutations to anticipate which patients might be at risk for sub-clonally driven therapy resistance...
May 16, 2024: Molecular Oncology
https://read.qxmd.com/read/38757364/investigating-the-molecular-mechanisms-of-microrna%C3%A2-409%C3%A2-3p-in-tumor-progression-towards-targeted-therapeutics-review
#77
REVIEW
Wenjie Xie, Zhichao Wang, Junke Wang, Xiu Wang, Hongzai Guan
MicroRNAs (miRNAs) are a group of non‑coding RNAs that exert master regulatory functions in post‑-transcriptional gene expression. Accumulating evidence shows that miRNAs can either promote or suppress tumorigenesis by regulating different target genes or pathways and may be involved in the occurrence of carcinoma. miR‑409‑3p is dysregulated in a variety of malignant cancers. It plays a fundamental role in numerous cellular biological processes, such as cell proliferation, apoptosis, migration, invasion, autophagy, angiogenesis and glycolysis...
July 2024: International Journal of Oncology
https://read.qxmd.com/read/38757348/targeted-delivery-of-interleukin-12-plasmid-into-hepg2-cells-through-folic-acid-conjugated-graphene-oxide-nanocarrier
#78
JOURNAL ARTICLE
Farshad Safari, Hassan Bardania, Ali Dehshahri, Somayeh Hallaj-Nezhadi, Arash Asfaram, Vahid Mohammadi, Marzieh Baneshi, Sima Bahramianpour, Negar Akrami, Bahman Khalvati, Ali Mirzaei
Successful gene therapy relies on carriers to transfer genetic materials with high efficiency and low toxicity in a targeted manner. To enhance targeted cell binding and uptake, we developed and synthesized a new gene delivery vector based on graphene oxide (GO) modified by branched polyethyleneimine (BPEI) and folic acid (FA). The GO-PEI-FA nanocarriers exhibit lower toxicity compared to unmodified PEI, as well as having the potential to efficiently condense and protect pDNA. Interestingly, increasing the polymer content in the polyplex formulation improved plasmid transfer ability...
May 16, 2024: Biotechnology Progress
https://read.qxmd.com/read/38757346/dual%C3%A2-regulated-oncolytic-adenovirus-carrying-ercc1-%C3%A2-sirna-gene-possesses-potent-antitumor-effect-on-ovarian-cancer-cells
#79
JOURNAL ARTICLE
Ting Zhao, Wei Ye, Rui Zhang, Xiaoyan Zhu, Qin Shi, Xiaofeng Xu, Weifeng Chen, Ling Xu, Yaping Meng
Ovarian cancer is a multifactorial and deadly disease. Despite significant advancements in ovarian cancer therapy, its incidence is on the rise and the molecular mechanisms underlying ovarian cancer invasiveness, metastasis and drug resistance remain largely elusive, resulting in poor prognosis. Oncolytic viruses armed with therapeutic transgenes of interest offer an attractive alternative to chemical drugs, which often face innate and acquired drug resistance. The present study constructed a novel oncolytic adenovirus carrying ERCC1 short interfering (si)RNA, regulated by hTERT and HIF promoters, termed Ad‑siERCC1...
July 2024: Molecular Medicine Reports
https://read.qxmd.com/read/38757343/daunorubicin-induces-gli1%C3%A2-dependent-apoptosis-in-colorectal-cancer-cell-lines
#80
JOURNAL ARTICLE
Bo Ram Kim, Dae Yeong Kim, Na Ly Tran, Bu Gyeom Kim, Sun Il Lee, Sang Hee Kang, Byung Yook Min, Wooyoung Hur, Sang Cheul Oh
Daunorubicin, also known as daunomycin, is a DNA‑targeting anticancer drug that is used as chemotherapy, mainly for patients with leukemia. It has also been shown to have anticancer effects in monotherapy or combination therapy in solid tumors, but at present it has not been adequately studied in colorectal cancer (CRC). In the present study, from a screening using an FDA‑approved drug library, it was found that daunorubicin suppresses GLI‑dependent luciferase reporter activity. Daunorubicin also increased p53 levels, which contributed to both GLI1 suppression and apoptosis...
June 2024: International Journal of Oncology
keyword
keyword
3703
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.